Renibus Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Southlake, TX, dedicated to transforming the treatment paradigm for cardio, renal, and metabolic diseases. Their innovative pipeline includes breakthrough products such as RBT-1, a drug in Phase 3 trials to reduce post-operative complications following cardiothoracic surgery, and RBT-9, a potent anti-inflammatory drug showing promise in improving clinical outcomes for high-risk patients with COVID-19.
With a focus on preventing disease progression, improving outcomes, and protecting against organ damage, Renibus Therapeutics is at the forefront of developing novel therapies like RBT-3 and RBT-2 to address critical medical needs in the field of cardiovascular and renal health. Through their dedication to research and development, Renibus Therapeutics aims to enhance and extend patients' lives by providing cutting-edge treatment options for complex diseases.
Generated from the website